Accessibility Menu

StageZero Life Sciences(OTC) GNWSF

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2011)-100%
5 Year-100%
1 Year-96%
1 Month-80%
N/A
StageZero Life Sciences last closing stock price
MetricPriceDate
Last closeUSD 0.002026-07-27
StageZero Life Sciences stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.002026-07-06
1 month-80.39%USD 0.012026-03-24
3 month-80.39%USD 0.012026-03-24
Year to date+100%USD 0.002025-12-18
1 year-95.61%USD 0.022025-07-02
3 year-97.89%USD 0.052023-07-28
5 year-99.72%USD 0.362021-07-28
Since inception-99.99%USD 9.602011-10-12

StageZero Life Sciences Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.50

Net Income (TTM)

-$0.40

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

N/A

GNWSF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About StageZero Life Sciences

StageZero Life Sciences Ltd. engages in the development and commercialization of proprietary molecular diagnostic tests for detection of diseases and for personalized health management, with a focus on cancer-related indications. Its products includes Sentinel Principle, and ColonSentry. The company was founded by Choong-Chin Liew and K. Wayne Marshall on February 20, 1997 and is headquartered in Richmond Hill, Canada.

Industry

Biotechnology

Sector

Health Care

Employees

40

CEO

James R. Howard-Tripp

Website

www.stagezerolifesciences.com

GNWSF Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

N/A

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

N/A

Payout Ratio

N/A

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

StageZero Life Sciences Performance Analysis

StageZero Life Sciences annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31USD 5,068,156N/A
20222022-12-31USD 3,795,076-25.1%
StageZero Life Sciences annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31USD -0.11N/A
20222022-12-31USD -0.118.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2024YOY CHG

Revenue

$0.50

N/A

Gross Profit

-$0.05

N/A

Gross Margin

-10.58%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

N/A

N/A

Net Income

-$0.40

N/A

EBITDA

-$0.41

N/A

Quarterly Fundamentals

Name
Q3 2024YOY CHG

Total Cash

$2.10

N/A

Total Debt

$2.09

N/A

Accounts Receivable

$0.09

N/A

Inventory

$0.05

N/A

Long Term Debt

$0.96

N/A

Short Term Debt

$1.13

N/A

Return on Assets

N/A

N/A

Return on Invested Capital

N/A

N/A

Free Cash Flow

$0.01

N/A

Operating Cash Flow

$0.01

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,684.24-0.00%
^DJIDJI
$53,254.61-0.01%
^IXICNASDAQ
$26,319.55-0.00%
BTCBitcoin
$78,890.00-0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
PCGPG&E
$13.27-0.20%
NVDANvidia
$220.78+0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.97+0.11%
CNHCNH Industrial
$11.83+0.01%

Questions About GNWSF

What is the current price of StageZero Life Sciences?

StageZero Life Sciences is trading at N/A per share.

What is the 52-week range for StageZero Life Sciences?

Over the past 52 weeks, StageZero Life Sciences has traded between N/A and N/A.

How much debt does StageZero Life Sciences have?

As of the most recent reporting period, StageZero Life Sciences reported total debt of $2.09M.

How much cash does StageZero Life Sciences have on hand?

StageZero Life Sciences reported $15.03K in cash and cash equivalents in its most recent financial results.

What is StageZero Life Sciences’s dividend yield?

StageZero Life Sciences does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services